Table 1 Baseline characteristics of patients: entire cohort and subgroups (main treatment indications)
From: Overview of the current use of levosimendan in France: a prospective observational cohort study
Patient characteristics | All patients (n = 602) | Cardiogenic shock (n = 250) | Decompensated heart failure (n = 127) | Cardiac surgery-relateda (n = 86) | Weaning from ECMO (n = 82) | P-value |
|---|---|---|---|---|---|---|
Age (years) | 57.5 ± 19.4 | 59 ± 18 | 57 ± 22 | 55 ± 22 | 56 ± 16 | 0.37 |
Male | 445 (73.9%) | 190 (76%) | 98 (77.2%) | 59 (68.6%) | 55 (67.1%) | 0.33 |
SOFA score at hospital admissionb | 5.5 ± 4.1 | 5.68 ± 4 | 4.67 ± 3.54 | 3.68 ± 3.75 | 8.61 ± 3.75 | < 0.001 |
SOFA score at levosimendan initiationc | 5.8 ± 4.4 | 6.11 ± 4.22 | 4.76 ± 4.96 | 3.87 ± 3.73 | 9.41 ± 3.48 | < 0.001 |
Previous atrial fibrillation | 150 (24.9%) | 52 (20.8%) | 41 (32.3%) | 20 (23.2%) | 16 (19.5%) | 0.02 |
Previous amiodarone treatment | 194 (32.2%) | 93 (37.2%) | 46 (36.2%) | 10 (11.6%) | 24 (29.2%) | < 0.001 |
Renal replacement therapy at levosimendan initiation | 65 (10.8%) | 21 (8.4%) | 8 (6.3%) | 4 (4.6%) | 27 (32.9%) | < 0.001 |
Ventricular support at levosimendan initiation | 171 (28.4%) | 63 (25.2%) | 11 (8.7%) | 8 (9.3%) | 80 (97.5%) | < 0.001 |
Concomitant use of inotropesd | 396 (65.8%) | 195 (78%) | 56 (44.1%) | 47 (54.6%) | 71 (86.6%) | < 0.001 |